skip to content »

Center for Cell and Gene Therapy

Houston, Texas

Center for Cell and Gene Therapy
Center for Cell and Gene Therapy
not shown on screen

Stephen M. Gottschalk, M.D.

Department of Pediatrics and Immunology
Section of Hematology-Oncology,
Baylor College of Medicine

Phone: 832-824-4179


  • M.D., Medical School, University of Göttingen, Germany
  • Research Fellowship in Cell Biology, Baylor College of Medicine, Houston, Texas
  • Pediatric Residency, Baylor College of Medicine, Houston, Texas
  • Postdoctoral Fellowship, Pediatric Hematology-Oncology, Texas Children's Cancer Center and Hematology Service, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas

Research Interests:

We are interested in cancer immunotherapy with antigen-specific T cells. This therapeutic approach has the major advantage of offering specific killing of malignant cells with minimal side effects. Our research is focused on Epstein-Barr virus (EBV)-specific T cells for the treatment of EBV-associated malignancies, and the use of genetically modified T cells for cancer immunotherapy. We are currently conducting Phase I/II clinical studies using EBV-specific T cells and chimeric antigen receptor (CAR) T cells. In the laboratory we are investigating genetic strategies on how to improve T-cell therapy for cancer.

Selected Publications:

  • Song XT, Turnis ME, Zhou X, Hong BX, Rollins L, Rabinovich B, Chen SY, Rooney CM, Gottschalk S. A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther. 2011 Jan;19(1):211-7

  • Shaffer D, Savoldo B, YI Z, Chow KKH, Kakarla S, Spencer D, Dotti G, Wu MF, Liu H, Kenney S, Gottschalk S. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 2011 Apr 21;117(16):4304-4314

  • Characterization and Treatment of Chronic Active Epstein-Barr Virus Disease: A 28 Year Experience in the United States. Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, Gottschalk S, Bollard CM, Rao VK, Marques A, Burbelo PD, Turk SP, Fulton R, Wayne AS, Little RF, Cairo MS, El-Mallawany NK, Fowler D, Sportes C, Bishop MR, Wilson W, Strauss SE. Blood 2011 Jun 2;117(22):5835-49

  • Salsman VS, Chow KKH, Shaffer DR, Kadikoy H, Li XN, Gerken C, Perlaky L, Metelitsa LS, Gao X, Bhattacharjee M, Hirschi K, Heslop HE, Gottschalk S, Ahmed N. Crosstalk between Medulloblastoma Cells and Endothelium Triggers a Strong Chemotactic Signal Recruiting T Lymphocytes to the Tumor Microenvironment. PloS One 2011;6(5):e20267

  • Hanley PJ, Shaffer DR, Cruz CRY, Ku S, Tzou B, Leen, AM, Liu H, Demmler-Harrison G, Rooney CM, Heslop HE, Brenner MK, Ahmed NM, Gottschalk S, and Bollard CM. Expansion of T cells targeting multiple antigens of CMV, EBV, and adenovirus to provide broad antiviral specificity after stem cell transplant. Cytotherapy 2011 Sep;13(8):976-86

  • Nakazawa Y, Huye LE, Salsman VS, Leen AM, Ahmed N, Rollins L, Dotti G, Gottschalk SM, Wilson MH, Rooney CM. PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor. Mol Ther 2011 Dec;19(12):2133-43

  • Gerdemann U, Katari U, Christin AS, Cruz CRY, Tripic T, Rousseau A, Gottschalk SM, Savoldo B, Vera JF, Heslop HE, Brenner MK, Bollard CM, Rooney CM, Leen AM. Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma. Mol Ther. 2011 Dec;19(12):2258-68

  • Ghazi A, Ashoori A, Hanley P, Salsman VS, Shaffer DR, Kew Y, Powell SZ, Grossman R, Grada Z, Scheurer ME, Hegde M, Leen AM, Bollard CM, Rooney CM, Heslop HE, Gottschalk S, Ahmed N. Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma. J Immunother 2012;35:159-168

  • Rainusso N, Salsman VS, Ghazi A, Hicks J, Gottschalk S, Rosen JM, Ahed NA. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Therapy 2012 Mar;19(3):212-7

  • Chia WK, Wang WW, Teo M, Tai WM, Lim WT, Tan EH, Leong SS, Sun L, Chen JJ, Gottschalk S*, Toh HC* (*shared senior authorship). A Phase II Study evaluating the Safety and Efficacy of an Adenovirus DLMP1-LMP2 transduced Dendritic Cell Vaccine in Patients with advanced metastatic Nasopharyngeal Carcinoma. Ann Oncol (2012) 23(4): 997-1005

    Eric A. Weaver EA, Mercier GT, Gottschalk S, Barry MA. T Cell-Biased Immune Responses Generated by a Mucosally-targeted Adenovirus-Sigma 1 Vaccine. Mucosal Immunity 2012 May;5(3):311-9

  • Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE, Perna SK, Ennamuri S, Gottschalk S, Brenner MK, Heslop HE, Rooney CM, Leen AM. Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections. Mol Ther. 2012; 20(8) 1622–1632

  • Hong B, Peng G, Berry L, Gottschalk S, Jung JJ, Chen SY, Hunag XF. Generating CTLs against the subdominant EBV LMP antigens by transit expression of an A20 inhibitor with EBV LMP proteins in human DCs. Gene Ther. 2012 Aug;19(8):818-27

  • Immunotherapeutic Strategies to Prevent and Treat Human Herpes Virus (HHV) 6 Reactivation Post Allogeneic Stem Cell Transplant. Gerdemann U, Keukens L, Keirnan JM, Katari UL, Nguyen CTQ, de Pagter AP, Ramos CA, Kennedy-Nasser A, Gottschalk SM, Heslop HE, Brenner MK, Rooney CM, Leen AM. Blood 2013 Jan 3;121(1):207-18

  • Chow KKH, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, Rainusso N, Wu M-F, Liu H, Kew Y, Grossman RG, Powell S, Lee D, Ahmed N, Gottschalk S. T cells redirected to EphA2 for the Immunotherapy of Glioblastoma. Mol Ther. Mol Ther. 2012 Oct 16 [Epub ahead of print]

E-mail this page to a friend